ImmuPharma (IMM.L) Stock Price

ImmuPharma Price

LSE·CLOSED
0.03
​
Market closed

Over the last 15 years ImmuPharma grew revenue by 10.9% annually, reaching 118,350.00 GBP. For ImmuPharma, the net margin of -6,906.6% is down versus -4,135.9% a few years ago. The consensus 12-month price target for ImmuPharma is 2.96 GBP, about 10,117.6% above where the stock trades today. Of 8 analysts, 0 rate the stock a buy — an overall Sell consensus.

ImmuPharma stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImmuPharma business model & stock analysis

ImmuPharma PLC is a biopharmaceutical company specializing in the development of drugs for the treatment of autoimmune diseases and cancer. The company was founded in 1999 and is headquartered in London, England. ImmuPharma's history began with the discovery of a new peptide extracted from the trail of a snail. This substance has potent immunomodulatory potential and can inhibit the growth of certain tumor cells. ImmuPharma recognized the potential of this discovery and began developing a new drug based on this peptide. ImmuPharma's business model is to develop innovative drugs and license or sell them to large pharmaceutical companies. The company works closely with leading scientists and experts in drug development to ensure the efficacy and safety of its products. ImmuPharma has focused on two main areas: autoimmune diseases and cancer. Autoimmune diseases are conditions in which the immune system malfunctions and attacks the body. The autoimmune diseases that ImmuPharma targets include lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and myasthenia gravis. ImmuPharma has also developed a drug called Lupuzor for the treatment of systemic lupus erythematosus (SLE). SLE is a severe autoimmune disease that causes inflammation and pain in various parts of the body. Lupuzor was developed as a first-in-class drug that regulates the immune system and reduces inflammation without compromising the body's normal defense function. In the field of cancer, ImmuPharma has also developed promising products that aim to inhibit tumor progression. The company has identified and tested a range of peptide- and protein-based drug candidates, including IPP-204106, which is used for the treatment of advanced prostate cancer. Last year, ImmuPharma also developed a new drug called Ureka for the treatment of urinary tract infections. Ureka is a bacterial toxin that specifically targets E. coli bacteria, which are the most common cause of urinary tract infections. In recent years, ImmuPharma has entered into several important partnerships to advance the development of its drugs. One partnership is with the Chinese company Avion Pharmaceuticals, which holds the marketing rights for Lupuzor in North America, Australia, and New Zealand. Another partnership is with the US company Orphan Reach, which supports the development and marketing of Ureka. Overall, ImmuPharma represents innovation and progress in drug development. The company is dedicated to a crucial purpose, seeking cures for those suffering from autoimmune diseases and cancer. Through a combination of scientific excellence and strategic partnerships, ImmuPharma has the potential to achieve significant therapeutic advancements and improve the lives of countless patients.

Frequently asked questions about ImmuPharma

The business model of ImmuPharma PLC is focused on developing and commercializing innovative drugs to treat serious medical conditions. The company's primary area of expertise lies in the field of autoimmune diseases and immune system disorders. ImmuPharma PLC aims to identify and advance biological compounds with the potential for improving patient outcomes and addressing unmet medical needs. By conducting research, clinical trials, and seeking regulatory approvals, ImmuPharma PLC strives to bring safe and effective therapeutic options to market, ultimately enhancing the quality of life for patients.

ImmuPharma PLC is primarily active in the pharmaceutical industry.

The main competitors of ImmuPharma PLC in the market include companies like Roche Holding AG, AstraZeneca PLC, Novartis AG, and GlaxoSmithKline PLC. These pharmaceutical companies operate in similar therapeutic areas and have developed competing drugs or treatments targeting the same diseases or medical conditions as ImmuPharma.

ImmuPharma PLC is a pharmaceutical company with a rich history and background. Founded in 1999, the company is focused on the development and commercialization of innovative therapeutics. ImmuPharma PLC has a diverse portfolio of drug candidates with a particular emphasis on autoimmune diseases and cancer. With extensive research and development capabilities, the company has made significant strides in advancing its drug candidates, including Lupuzor™ for lupus and Nucant for oncology. ImmuPharma PLC's commitment to scientific excellence and dedication to improving patient outcomes has positioned it as a leading player in the pharmaceutical industry.

ImmuPharma PLC, a leading pharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed a Phase III clinical trial for its drug candidate, LupuzorTM, for the treatment of systemic lupus erythematosus (SLE). The trial showed promising results, demonstrating the drug's potential to address this debilitating autoimmune disease. Furthermore, ImmuPharma PLC secured a global licensing agreement with Avion Pharmaceuticals for the commercialization of LupuzorTM in the United States. This partnership ensures widespread access to this potentially life-changing treatment for SLE patients. ImmuPharma PLC's unwavering commitment to scientific innovation and partnership development has propelled it towards these remarkable achievements.

ImmuPharma PLC is primarily present in various countries and regions worldwide. The company has a global presence, with key markets and operations in Europe, including the United Kingdom, France, and Switzerland. ImmuPharma also extends its reach to other areas, such as Asia, North America, and South America. Through strategic partnerships and collaborations, ImmuPharma aims to expand its market presence and ensure accessibility of its innovative healthcare solutions to a diverse range of patients and healthcare professionals internationally.

ImmuPharma PLC represents a values-driven corporate philosophy focused on innovation, scientific excellence, and delivering groundbreaking solutions to patients. The company is committed to enhancing human health through its cutting-edge research and development in the field of immunotherapy. ImmuPharma PLC places a strong emphasis on collaboration, fostering strategic partnerships with leading institutions and experts in the industry. With a steadfast commitment to patient well-being, ImmuPharma PLC strives to bring groundbreaking treatments to market, revolutionizing healthcare and improving quality of life.

Analysts currently set an average price target of 2.96 GBP for the ImmuPharma stock (median: 2.96 GBP), implying +2.2 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the ImmuPharma stock: 0 recommend buying, 2 holding and 6 selling. For 2026, analysts expect ImmuPharma to generate revenue of 74,216.00 GBP and earnings per share of -0.03 GBP.

Converted at the current exchange rate, the ImmuPharma share trades at 0.03 EUR (0.03 GBP).

The ImmuPharma share (IMM.L) is listed on 5 stock exchanges, including: London (IMM.L), Frankfurt (25I.F), München (25I.MU), Düsseldorf (25I.DU).

ImmuPharma PLC is a global biopharmaceutical company focused on developing therapeutics for the treatment of autoimmune diseases and cancer. It is headquartered in London, with subsidiaries in France and the USA. The company's business model is based on the identification, development, and commercialization of drugs made from peptides and proteins. It specializes in platform technologies that simplify the discovery and characterization of peptides and proteins. The company operates in multiple therapeutic areas, including the treatment of autoimmune diseases like lupus and multiple sclerosis. It has developed a drug called Lupuzor, currently in Phase III clinical trials and plans to market it in the USA and Europe once approved by regulatory authorities. In addition, ImmuPharma PLC is focused on cancer research and has developed a peptide called IPP-204106 that targets the CXCR4 receptor, which plays an important role in many types of cancer. The company is working on testing this peptide in clinical trials with patients who have advanced cancer. ImmuPharma PLC has also developed a platform technology called Ureka, which is specifically designed for the treatment of pain and inflammation. The company is currently working on several projects that utilize this technology, including peptides for the treatment of arthritis pain and chronic cough. In addition to developing its own products, ImmuPharma PLC collaborates with other companies to leverage their platform technologies and clinical expertise for the development of new treatments. It has partnerships with major pharmaceutical companies such as AstraZeneca and Ipsen to jointly develop new drugs. ImmuPharma PLC is listed on the London Stock Exchange and has a strong financial foundation. It has successfully completed multiple funding rounds and has a diversified investor base, including large institutional investors and private individuals. In summary, ImmuPharma PLC's business model is based on the development of innovative therapeutics for autoimmune diseases and cancer. The company specializes in platform technologies for the identification and characterization of peptides and proteins. It operates in multiple therapeutic areas and collaborates closely with other companies to develop new drugs. With its experience, expertise, and financial stability, ImmuPharma PLC is well positioned to continue its success.

The expected revenue of ImmuPharma is 74,216.00 GBP. This figure is based on current financial data and reflects the company's business performance.

The expected profit of ImmuPharma is -13.16 M GBP. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of ImmuPharma is currently -1.08. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ImmuPharma stock.

The price-to-sales ratio (P/S) of ImmuPharma is currently 191.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ImmuPharma stock.

The Eulerpool Quality Score for ImmuPharma is 2/10.

The ISIN of ImmuPharma is GB0033711010. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of ImmuPharma is A0BMC4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of ImmuPharma is IMM.L. The ticker symbol is used to trade ImmuPharma shares on the stock exchange.

Fair ValueTerminal
0.02 GBP
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
GBP
Initial public offering
Oct 28, 2003
ISIN
GB0033711010
Cusip
G4720G108
Sedol
3371101
Market capitalization
12.06 M GBPMicro Cap
52-Week Range
PEG
4.61
P/E ratio
P/Ee 2026
-1.08
P/Ee 2027
-0.80
P/Ee 2028
-1.18
P/Ee 2029
-1.22
P/Ee 2030
-1.18
P/S
P/Se
191.37
EV/EBIT
—
P/B Ratio
17.55
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-263.18 %
Last updated Nov 22, 2026, 3:45 AM

ImmuPharma Ticker

DÜSSELDORF · 25I.DUFRANKFURT · 25I.FLONDON · IMM.LLONDON STOCK EXCHANGE · IMM.LMUNICH · 25I.MU

ImmuPharma FIGI

IMM:LN · BBG000C01SG5IMM:EO · BBG000R5VWP6IMM:XL · BBG000R5VZZ8IMM:E1 · BBG000R5W262IMM:XT · BBG000R5W2Y1IMM:XW · BBG000R5W388IMMEUR:EO · BBG000R9K8Q2IMMEUR:E1 · BBG000R9KGQ4IMMEUR:XT · BBG000R9KGY5IMMEUR:XW · BBG000R9KH64IMM:EU · BBG000RF65R925I:GR · BBG000SVS5S8

All fundamentals and in-depth analysis of ImmuPharma

Our stock analysis for ImmuPharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuPharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.